6 research outputs found
P-270 The results of reconstructive and plastic surgery of the pelvic floor after combined removal of retroperitoneal tumors of pelvis
P-269 Results of combined surgical treatment locally advanced cancer of the rectum with germination in genital organs
P127
To determine diagnostic importance of DNA methylation in patients with chronic atrophic gastritis and induction of βCorreaβ cascade for gastric cancer prevention.
Material and methods: This present study included 80 patients with chronic atrophic gastritis associated with Helicobacter pylori. Diagnoses were confirmed by endoscopic, morphologic, serologic examinations. Age of patients varied from 17 to 78 years old. There were 52 (65%) males and 28 (35%) females. The control group consisted of 32 patients with morphological verified diagnosis of stage IβII gastric cancer. Examination with the purpose to determine hypermethylation of DNA was performed simultaneously in biopsy materials and blood plasma. Provoking factors of hypermethylation in 4 tumorsβ genes, APE, E-Cadherin, T1MP3, hMLHI were determined by quantitative methylation with use of Polymerase Chain Reaction. To evaluate the level of methylation we compared the analysisβ results of biopsy and blood plasma tests. Blood serum samples and biopsy specimens were collected at diagnosis until the therapy is started. All patients with chronic atrophic gastritis infected with H. pylori underwent anti-H. pylori therapy according to the protocol. Chronic atrophic gastritis was found at morphologic examination in 40 (50%) patients according to βCorreaβ cascade. 36 (45%) patients had intestinal metaplasia, and 4 (5%) patients had dysplasia. Reaction was considered to be positive in cases, when the level of methylation in genes listed above was higher in blood serum than in biopsy materials.
Results: High concentrations of methylated APE, T1MP3 and hMLIH in genes were found in blood serum of 8 (10%) patients. In the control group, all 32 patients with gastric cancer had high methylation level in blood serum. In the remaining 72 (90%) patients, no high concentration of DNA methylation was found. After the 2-nd course of anti-H. pylori therapy, patients underwent morphologic and endoscopic examinations according to the protocol. Eradication of H. pylori was determined in 86% patients who received therapy. Intestinal metaplasia decreased from 45% to 25% (20 patients). Mild dysplasia was found in 1.2% of cases. Repeated analysis of methylation level showed its decrease after anti-H. pylori therapy in 4 (50%) out of 8 patients.
Conclusion: Genetic tests show that DNA methylation in patients with chronic atrophic gastritis has high diagnostic importance. Anti-H. pylori therapy at the different stages of βCorreaβ cascade has high level of induction in transforming into non invase gastric cancer
Π Π΅Π·ΡΠ»ΡΡΠ°ΡΡ Π½Π΅ΠΎΠ°Π΄ΡΡΠ²Π°Π½ΡΠ½ΠΎΠΉ Ρ ΠΈΠΌΠΈΠΎΠ»ΡΡΠ΅Π²ΠΎΠΉ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ Π±ΠΎΠ»ΡΠ½ΡΡ ΠΌΠ΅ΡΡΠ½ΠΎ-ΡΠ°ΡΠΏΡΠΎΡΡΡΠ°Π½Π΅Π½Π½ΡΠΌ ΡΠ°ΠΊΠΎΠΌ ΠΏΡΡΠΌΠΎΠΉ ΠΊΠΈΡΠΊΠΈ. Π‘ΡΠ°Π²Π½ΠΈΡΠ΅Π»ΡΠ½Π°Ρ ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΡΡΡ ΡΠ΅ΠΆΠΈΠΌΠΎΠ² Π³ΠΈΠΏΠΎΡΡΠ°ΠΊΡΠΈΠΎΠ½ΠΈΡΠΎΠ²Π°Π½ΠΈΡ ΠΈ ΠΊΠ»Π°ΡΡΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ ΡΡΠ°ΠΊΡΠΈΠΎΠ½ΠΈΡΠΎΠ²Π°Π½ΠΈΡ
Objective: comparison of the effectiveness of the results of neoadjuvant chemoradiotherapy in patients with locally advanced rectal cancer using classical and hypofractionated schedule of radiation therapy.Materials and methods. This study is based on a retrospective analysis of a database of patients with locally advanced rectal cancer (T3CβD, positive circumferential resection margin or T4) who underwent a prolonged course of neoadjuvant chemoradiotherapy followed by surgery. The patients were divided into two groups: the first (main) group, 71 patients who received a course of chemoradiotherapy in hypofractionation schedule as part of neoadjuvant treatment (4 Gy Γ 40 Gy, 3 fractions per week) in combination with chemotherapy with capecitabine 1650 mg / m2 in two doses on weekdays. The second group (control group) included 79 patients who treated with long-course chemoradiotherapy in the classic fractionation mode (2 Gy Γ 50β58 Gy, 5 fractions per week) in combination with chemotherapy with capecitabine 1650 mg / m2 in two doses on weekdays. In the preoperative period, along with chemoradiotherapy, 4β8 courses of the systemic chemotherapy in the CapOx mode was used. The primary endpoint of this study was pathological complete response. Secondary endpoints included the seve rity of early radiation and hematological toxicity, the incidence of local recurrence, distant metastases, overall and disease-free survival. Results. The study included 150 patients. The overall frequency of acute radiation toxicity of grade IIIβIV was 5.6 % in the main group and 8.9 % in the control group (p = 0.658), from them hematological toxicity β 2.82 % and 7.6 %, respectively (p = 0.350), skin and pelvic organ toxicity β 2.82 % and 1.3 %, respectively (p = 0.926). Complete pathological response of III degree in the groups achieved 22.5 % and 19 %, respectively (p = 0.593), grade IV β 18.3 % and 15.2 %, respectively (p = 0.829). In the main and control groups, 4.2 % and 3.8 % of local recurrence were registered, respectively (p = 0.954; hazard ratio (HR) 1.05; 95 % confidence interval (CI) 0.21β5.22). The median time of disease-free survival was 39.4 months. The three-year disease-free survival in the main group was 73.2 % and in the control group 64.6 %, respectively (p = 0.353; HR 0.79; 95 % CI 0.42β1.35). The three-year overall survival in the main and control groups were 84.5 % and 82.3 %, respectively (p = 0.743; HR 0.87; 95 % CI 0.39β1.92). Conclusions. The hypofractionation schedule can be considered as an alternative and not inferior to the standard dose fractionation regimen in a prolonged course of neoadjuvant chemoradiotherapy in patients with locally advanced rectal cancer.Β Π¦Π΅Π»Ρ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ β ΡΡΠ°Π²Π½Π΅Π½ΠΈΠ΅ ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΡΡΠΈ ΡΠ΅Π·ΡΠ»ΡΡΠ°ΡΠΎΠ² Π½Π΅ΠΎΠ°Π΄ΡΡΠ²Π°Π½ΡΠ½ΠΎΠΉ Ρ
ΠΈΠΌΠΈΠΎΠ»ΡΡΠ΅Π²ΠΎΠΉ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ Π±ΠΎΠ»ΡΠ½ΡΡ
ΠΌΠ΅ΡΡΠ½ΠΎ-ΡΠ°ΡΠΏΡΠΎΡΡΡΠ°Π½Π΅Π½Π½ΡΠΌ ΡΠ°ΠΊΠΎΠΌ ΠΏΡΡΠΌΠΎΠΉ ΠΊΠΈΡΠΊΠΈ ΠΏΡΠΈ ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π½ΠΈΠΈ ΠΊΠ»Π°ΡΡΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ ΠΈ Π³ΠΈΠΏΠΎΡΡΠ°ΠΊΡΠΈΠΎΠ½Π½ΠΎΠ³ΠΎ ΡΠ΅ΠΆΠΈΠΌΠ° Π»ΡΡΠ΅Π²ΠΎΠΉ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ. ΠΠ°ΡΠ΅ΡΠΈΠ°Π»Ρ ΠΈ ΠΌΠ΅ΡΠΎΠ΄Ρ. Π Π°Π±ΠΎΡΠ° ΠΎΡΠ½ΠΎΠ²Π°Π½Π° Π½Π° ΡΠ΅ΡΡΠΎΡΠΏΠ΅ΠΊΡΠΈΠ²Π½ΠΎΠΌ Π°Π½Π°Π»ΠΈΠ·Π΅ Π±Π°Π·Ρ Π΄Π°Π½Π½ΡΡ
Π±ΠΎΠ»ΡΠ½ΡΡ
ΠΌΠ΅ΡΡΠ½ΠΎ-ΡΠ°ΡΠΏΡΠΎΡΡΡΠ°Π½Π΅Π½Π½ΡΠΌ ΡΠ°ΠΊΠΎΠΌ ΠΏΡΡΠΌΠΎΠΉ ΠΊΠΈΡΠΊΠΈ (T3CβD, ΠΏΠΎΠ»ΠΎΠΆΠΈΡΠ΅Π»ΡΠ½ΡΠΉ ΡΠΈΡΠΊΡΠ»ΡΡΠ½ΡΠΉ ΠΊΡΠ°ΠΉ ΡΠ΅Π·Π΅ΠΊΡΠΈΠΈ Π»ΠΈΠ±ΠΎ T4), ΠΊΠΎΡΠΎΡΡΠΌ Π±ΡΠ» ΠΏΡΠΎΠ²Π΅Π΄Π΅Π½ ΠΏΡΠΎΠ»ΠΎΠ½Π³ΠΈΡΠΎΠ²Π°Π½Π½ΡΠΉ ΠΊΡΡΡ Π½Π΅ΠΎΠ°Π΄ΡΡΠ²Π°Π½ΡΠ½ΠΎΠΉ Ρ
ΠΈΠΌΠΈΠΎΠ»ΡΡΠ΅Π²ΠΎΠΉ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ Ρ ΠΏΠΎΡΠ»Π΅Π΄ΡΡΡΠΈΠΌ ΠΎΠΏΠ΅ΡΠ°ΡΠΈΠ²Π½ΡΠΌ Π²ΠΌΠ΅ΡΠ°ΡΠ΅Π»ΡΡΡΠ²ΠΎΠΌ. ΠΠ°ΡΠΈΠ΅Π½ΡΡ Π±ΡΠ»ΠΈ ΡΠ°Π·Π΄Π΅Π»Π΅Π½Ρ Π½Π° 2 Π³ΡΡΠΏΠΏΡ: 1-Ρ (ΠΎΡΠ½ΠΎΠ²Π½ΡΡ) Π³ΡΡΠΏΠΏΡ (n = 71) ΡΠΎΡΡΠ°Π²ΠΈΠ»ΠΈ ΠΏΠ°ΡΠΈΠ΅Π½ΡΡ, ΠΊΠΎΡΠΎΡΡΠΌ Π² ΡΠ°ΠΌΠΊΠ°Ρ
Π½Π΅ΠΎΠ°Π΄ΡΡΠ²Π°Π½ΡΠ½ΠΎΠ³ΠΎ Π»Π΅ΡΠ΅Π½ΠΈΡ Π±ΡΠ» Π²ΡΠΏΠΎΠ»Π½Π΅Π½ ΠΊΡΡΡ Ρ
ΠΈΠΌΠΈΠΎΠ»ΡΡΠ΅Π²ΠΎΠΉ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ Π² ΡΠ΅ΠΆΠΈΠΌΠ΅ Π³ΠΈΠΏΠΎΡΡΠ°ΠΊΡΠΈΠΎΠ½ΠΈΡΠΎΠ²Π°Π½ΠΈΡ (ΡΠ°Π·ΠΎΠ²Π°Ρ ΠΎΡΠ°Π³ΠΎΠ²Π°Ρ Π΄ΠΎΠ·Π° 4 ΠΡ, ΡΡΠΌΠΌΠ°ΡΠ½Π°Ρ ΠΎΡΠ°Π³ΠΎΠ²Π°Ρ Π΄ΠΎΠ·Π° 40 ΠΡ, 3 ΡΡΠ°ΠΊΡΠΈΠΈ Π² Π½Π΅Π΄Π΅Π»Ρ) Π² ΠΊΠΎΠΌΠ±ΠΈΠ½Π°ΡΠΈΠΈ Ρ Ρ
ΠΈΠΌΠΈΠΎΡΠ΅ΡΠ°ΠΏΠΈΠ΅ΠΉ ΠΊΠ°ΠΏΠ΅ΡΠΈΡΠ°Π±ΠΈΠ½ΠΎΠΌ 1650 ΠΌΠ³ / ΠΌ2 Π² 2 ΠΏΡΠΈΠ΅ΠΌΠ° Π² Π±ΡΠ΄Π½ΠΈΠ΅ Π΄Π½ΠΈ. ΠΠΎ 2-Ρ (ΠΊΠΎΠ½ΡΡΠΎΠ»ΡΠ½ΡΡ) Π³ΡΡΠΏΠΏΡ Π±ΡΠ»ΠΎ Π²ΠΊΠ»ΡΡΠ΅Π½ΠΎ 79 ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ², ΠΊΠΎΡΠΎΡΡΠΌ Π±ΡΠ» ΠΏΡΠΎΠ²Π΅Π΄Π΅Π½ ΠΊΡΡΡ Ρ
ΠΈΠΌΠΈΠΎΠ»ΡΡΠ΅Π²ΠΎΠΉ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ Π² ΡΠ΅ΠΆΠΈΠΌΠ΅ ΠΊΠ»Π°ΡΡΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ ΡΡΠ°ΠΊΡΠΈΠΎΠ½ΠΈΡΠΎΠ²Π°Π½ΠΈΡ (ΡΠ°Π·ΠΎΠ²Π°Ρ ΠΎΡΠ°Π³ΠΎΠ²Π°Ρ Π΄ΠΎΠ·Π° 2 ΠΡ, ΡΡΠΌΠΌΠ°ΡΠ½Π°Ρ ΠΎΡΠ°Π³ΠΎΠ²Π°Ρ Π΄ΠΎΠ·Π° 50β58 ΠΡ, 5 ΡΡΠ°ΠΊΡΠΈΠΉ Π² Π½Π΅Π΄Π΅Π»Ρ) Π² ΠΊΠΎΠΌΠ±ΠΈΠ½Π°ΡΠΈΠΈ Ρ Ρ
ΠΈΠΌΠΈΠΎΡΠ΅ΡΠ°ΠΏΠΈΠ΅ΠΉ ΠΊΠ°ΠΏΠ΅ΡΠΈΡΠ°Π±ΠΈΠ½ΠΎΠΌ 1650 ΠΌΠ³ / ΠΌ2 Π² 2 ΠΏΡΠΈΠ΅ΠΌΠ° Π² Π±ΡΠ΄Π½ΠΈΠ΅ Π΄Π½ΠΈ. Π ΠΏΠ΅ΡΠΈΠΎΠΏΠ΅ΡΠ°ΡΠΈΠΎΠ½Π½ΠΎΠΌ ΠΏΠ΅ΡΠΈΠΎΠ΄Π΅ Π½Π°ΡΡΠ΄Ρ Ρ Ρ
ΠΈΠΌΠΈΠΎΠ»ΡΡΠ΅Π²ΠΎΠΉ ΡΠ΅ΡΠ°ΠΏΠΈΠ΅ΠΉ ΠΏΡΠΈΠΌΠ΅Π½ΡΠ»Π°ΡΡ ΡΠΈΡΡΠ΅ΠΌΠ½Π°Ρ Ρ
ΠΈΠΌΠΈΠΎΡΠ΅ΡΠ°ΠΏΠΈΡ ΠΏΠΎ ΡΡ
Π΅ΠΌΠ΅ CapOx 4β8 ΠΊΡΡΡΠΎΠ². ΠΡΠ½ΠΎΠ²Π½ΠΎΠΉ ΠΎΡΠ΅Π½ΠΈΠ²Π°Π΅ΠΌΡΠΉ ΠΏΠΎΠΊΠ°Π·Π°ΡΠ΅Π»Ρ β Π»Π΅ΡΠ΅Π±Π½ΡΠΉ ΠΏΠ°ΡΠΎΠΌΠΎΡΡΠΎΠ· (ΠΏΠΎ Dworak). ΠΠΎΠΏΠΎΠ»Π½ΠΈΡΠ΅Π»ΡΠ½ΡΠ΅ ΠΎΡΠ΅Π½ΠΈΠ²Π°Π΅ΠΌΡΠ΅ ΠΏΠΎΠΊΠ°Π·Π°ΡΠ΅Π»ΠΈ: ΡΡΠ΅ΠΏΠ΅Π½Ρ ΡΡΠΆΠ΅ΡΡΠΈ ΡΠ°Π½Π½ΠΈΡ
Π»ΡΡΠ΅Π²ΡΡ
ΠΏΠΎΠ²ΡΠ΅ΠΆΠ΄Π΅Π½ΠΈΠΉ ΠΈ Π³Π΅ΠΌΠ°ΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΎΠΉ ΡΠΎΠΊΡΠΈΡΠ½ΠΎΡΡΠΈ, ΡΠ°ΡΡΠΎΡΠ° ΡΠ°Π·Π²ΠΈΡΠΈΡ ΠΌΠ΅ΡΡΠ½ΡΡ
ΡΠ΅ΡΠΈΠ΄ΠΈΠ²ΠΎΠ², ΠΎΡΠ΄Π°Π»Π΅Π½Π½ΡΡ
ΠΌΠ΅ΡΠ°ΡΡΠ°Π·ΠΎΠ², ΠΎΠ±ΡΠ°Ρ ΠΈ Π±Π΅Π·ΡΠ΅ΡΠΈΠ΄ΠΈΠ²Π½Π°Ρ Π²ΡΠΆΠΈΠ²Π°Π΅ΠΌΠΎΡΡΡ. Π Π΅Π·ΡΠ»ΡΡΠ°ΡΡ. Π ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠ΅ Π²ΠΊΠ»ΡΡΠ΅Π½ΠΎ 150 ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ². ΠΠ±ΡΠ°Ρ ΡΠ°ΡΡΠΎΡΠ° ΡΠ°Π½Π½Π΅ΠΉ Π»ΡΡΠ΅Π²ΠΎΠΉ ΡΠΎΠΊΡΠΈΡΠ½ΠΎΡΡΠΈ III ΠΈ IV ΡΡΠ΅ΠΏΠ΅Π½ΠΈ ΡΡΠΆΠ΅ΡΡΠΈ ΡΠΎΡΡΠ°Π²ΠΈΠ»Π° 5,6 % Π² ΠΎΡΠ½ΠΎΠ²Π½ΠΎΠΉ Π³ΡΡΠΏΠΏΠ΅ ΠΈ 8,9 % Π² ΠΊΠΎΠ½ΡΡΠΎΠ»ΡΠ½ΠΎΠΉ Π³ΡΡΠΏΠΏΠ΅ (Ρ = 0,658), ΠΈΠ· Π½ΠΈΡ
ΡΠ°ΡΡΠΎΡΠ° Π³Π΅ΠΌΠ°ΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΎΠΉ ΡΠΎΠΊΡΠΈΡΠ½ΠΎΡΡΠΈ β 2,82 ΠΈ 7,6 % ΡΠΎΠΎΡΠ²Π΅ΡΡΡΠ²Π΅Π½Π½ΠΎ (Ρ = 0,350), ΡΠ°ΡΡΠΎΡΠ° ΡΠΎΠΊΡΠΈΡΠ½ΠΎΡΡΠΈ ΡΠΎ ΡΡΠΎΡΠΎΠ½Ρ ΠΊΠΎΠΆΠΈ ΠΈ ΡΠΌΠ΅ΠΆΠ½ΡΡ
ΠΎΡΠ³Π°Π½ΠΎΠ² ΠΌΠ°Π»ΠΎΠ³ΠΎ ΡΠ°Π·Π° β 2,82 ΠΈ 1,3 % ΡΠΎΠΎΡΠ²Π΅ΡΡΡΠ²Π΅Π½Π½ΠΎ (Ρ = 0,926). ΠΠ΅ΡΠ΅Π±Π½ΡΠΉ ΠΏΠ°ΡΠΎΠΌΠΎΡΡΠΎΠ· III ΡΡΠ΅ΠΏΠ΅Π½ΠΈ Π² 1-ΠΉ ΠΈ 2-ΠΉ Π³ΡΡΠΏΠΏΠ°Ρ
Π΄ΠΎΡΡΠΈΠ³Π½ΡΡ Π² 22,5 ΠΈ 19 % ΡΠ»ΡΡΠ°Π΅Π² ΡΠΎΠΎΡΠ²Π΅ΡΡΡΠ²Π΅Π½Π½ΠΎ (p = 0,593), Π»Π΅ΡΠ΅Π±Π½ΡΠΉ ΠΏΠ°ΡΠΎΠΌΠΎΡΡΠΎΠ· IV ΡΡΠ΅ΠΏΠ΅Π½ΠΈ β Π² 18,3 ΠΈ 15,2 % ΡΠ»ΡΡΠ°Π΅Π² ΡΠΎΠΎΡΠ²Π΅ΡΡΡΠ²Π΅Π½Π½ΠΎ (p = 0,829). Π ΠΎΡΠ½ΠΎΠ²Π½ΠΎΠΉ ΠΈ Π² Π³ΡΡΠΏΠΏΠ΅ ΠΊΠΎΠ½ΡΡΠΎΠ»Ρ Π·Π°ΡΠ΅Π³ΠΈΡΡΡΠΈΡΠΎΠ²Π°Π½ΠΎ 4,2 ΠΈ 3,8 % ΡΠ΅ΡΠΈΠ΄ΠΈΠ²ΠΎΠ² ΡΠΎΠΎΡΠ²Π΅ΡΡΡΠ²Π΅Π½Π½ΠΎ (p = 0,954; ΠΎΡΠ½ΠΎΡΠ΅Π½ΠΈΠ΅ ΡΠΈΡΠΊΠΎΠ² (ΠΠ ) 1,05; 95 % Π΄ΠΎΠ²Π΅ΡΠΈΡΠ΅Π»ΡΠ½ΡΠΉ ΠΈΠ½ΡΠ΅ΡΠ²Π°Π» (ΠΠ) 0,21β5,22). ΠΠ΅Π΄ΠΈΠ°Π½Π° Π²ΡΠ΅ΠΌΠ΅Π½ΠΈ Π±Π΅Π· ΠΏΡΠΎΠ³ΡΠ΅ΡΡΠΈΡΠΎΠ²Π°Π½ΠΈΡ Π² ΠΎΠ±ΡΠ΅ΠΉ Π²ΡΠ±ΠΎΡΠΊΠ΅ ΡΠΎΡΡΠ°Π²ΠΈΠ»Π° 39,4 ΠΌΠ΅Ρ. ΠΠΎΠΊΠ°Π·Π°ΡΠ΅Π»Ρ 3-Π»Π΅ΡΠ½Π΅ΠΉ Π²ΡΠΆΠΈΠ²Π°Π΅ΠΌΠΎΡΡΠΈ Π±Π΅Π· ΠΏΡΠΎΠ³ΡΠ΅ΡΡΠΈΡΠΎΠ²Π°Π½ΠΈΡ Π² ΠΎΡΠ½ΠΎΠ²Π½ΠΎΠΉ Π³ΡΡΠΏΠΏΠ΅ ΡΠΎΡΡΠ°Π²ΠΈΠ» 73,2 %, Π° Π² Π³ΡΡΠΏΠΏΠ΅ ΠΊΠΎΠ½ΡΡΠΎΠ»Ρ β 64,6 % (p = 0,353; ΠΠ 0,79; 95 % ΠΠ 0,42β1,35), ΠΏΠΎΠΊΠ°Π·Π°ΡΠ΅Π»Ρ 3-Π»Π΅ΡΠ½Π΅ΠΉ ΠΎΠ±ΡΠ΅ΠΉ Π²ΡΠΆΠΈΠ²Π°Π΅ΠΌΠΎΡΡΠΈ β 84,5 ΠΈ 82,3 % Π² ΠΎΡΠ½ΠΎΠ²Π½ΠΎΠΉ ΠΈ ΠΊΠΎΠ½ΡΡΠΎΠ»ΡΠ½ΠΎΠΉ Π³ΡΡΠΏΠΏΠ°Ρ
ΡΠΎΠΎΡΠ²Π΅ΡΡΡΠ²Π΅Π½Π½ΠΎ (p = 0,743; ΠΠ 0,87; 95 % ΠΠ 0,39β1,92). ΠΡΠ²ΠΎΠ΄Ρ. Π’Π°ΠΊΠΈΠΌ ΠΎΠ±ΡΠ°Π·ΠΎΠΌ, ΡΠ΅ΠΆΠΈΠΌ Π³ΠΈΠΏΠΎΡΡΠ°ΠΊΡΠΈΠΎΠ½ΠΈΡΠΎΠ²Π°Π½ΠΈΡ ΠΌΠΎΠΆΠ΅Ρ ΡΠ°ΡΡΠΌΠ°ΡΡΠΈΠ²Π°ΡΡΡΡ ΠΊΠ°ΠΊ Π°Π»ΡΡΠ΅ΡΠ½Π°ΡΠΈΠ²Π½ΡΠΉ ΠΈ Π½Π΅ ΡΡΡΡΠΏΠ°ΡΡΠΈΠΉ ΡΡΠ°Π½Π΄Π°ΡΡΠ½ΠΎΠΌΡ ΡΠ΅ΠΆΠΈΠΌΡ ΡΡΠ°ΠΊΡΠΈΠΎΠ½ΠΈΡΠΎΠ²Π°Π½ΠΈΡ Π΄ΠΎΠ·Ρ Π² ΠΏΡΠΎΠ»ΠΎΠ½Π³ΠΈΡΠΎΠ²Π°Π½Π½ΠΎΠΌ ΠΊΡΡΡΠ΅ Π½Π΅ΠΎΠ°Π΄ΡΡΠ²Π°Π½ΡΠ½ΠΎΠΉ Ρ
ΠΈΠΌΠΈΠΎΠ»ΡΡΠ΅Π²ΠΎΠΉ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ Π±ΠΎΠ»ΡΠ½ΡΡ
ΠΌΠ΅ΡΡΠ½ΠΎΡΠ°ΡΠΏΡΠΎΡΡΡΠ°Π½Π΅Π½Π½ΡΠΌ ΡΠ°ΠΊΠΎΠΌ ΠΏΡΡΠΌΠΎΠΉ ΠΊΠΈΡΠΊΠΈ.